Back to top
more

Entrada Therapeutics (TRDA)

(Delayed Data from NSDQ)

$15.74 USD

15.74
154,395

+0.18 (1.16%)

Updated Jul 10, 2024 04:00 PM ET

After-Market: $15.69 -0.05 (-0.32%) 4:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (68 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug

by Zacks Equity Research

The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.

Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?

by Zacks Equity Research

Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Best Momentum Stocks to Buy for July 9th

by Zacks Equity Research

CVNA, AL and TRDA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 9, 2024.

Kymera's (KYMR) Partner SNY to Expand Ongoing HS and AD Studies

by Zacks Equity Research

Kymera (KYMR) announces expansion plans of ongoing mid-stage studies on KT-474 (SAR444656) by partner Sanofi.

New Strong Buy Stocks for July 9th

by Zacks Equity Research

CVNA, TRDA, BMBL, APEI and AL have been added to the Zacks Rank #1 (Strong Buy) List on July 9, 2024.

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 37.1% in Entrada Therapeutics (TRDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

New Strong Sell Stocks for March 18th

by Zacks Equity Research

ACNB, AMPH and TRDA have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2024.

Exelixis (EXEL) Posts Preliminary 2023 Results, to Cut 13% Jobs

by Zacks Equity Research

Exelixis (EXEL) posts preliminary results for 2023 and issues 2024 guidance. The company is set to cut its workforce by 13% in the first quarter of 2024.

Bayer (BAYRY) Elinzanetant Meets Goals in Late-Stage Studies

by Zacks Equity Research

Bayer's (BAYRY) experimental candidate, elinzanetant, for the non-hormonal treatment of moderate to severe vasomotor symptoms, meets primary and secondary goals in phase III studies.

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

by Zacks Equity Research

Amicus (FOLD) posts preliminary results for full-year 2023. The company also provides a strategic outlook for 2024.

Pacira (PCRX) Preliminary '23 Revenues Solid, Exparel Strong

by Zacks Equity Research

Pacira (PCRX) posts preliminary revenues for the fourth quarter and full year 2023.

Collegium (COLL) Shares Rise on Financial Outlook for 2024

by Zacks Equity Research

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

by Zacks Equity Research

Assertio (ASRT) appoints Heather Mason as its interim CEO as its current CEO, Dan Peisert, steps down from his role. Shares of the company fall on the same.

Bristol Myers (BMY) NSCLC Drug Application Gets EMA Validation

by Zacks Equity Research

Bristol Myers' (BMY) repotrectinib is under review in the European Union for the treatment of locally advanced or metastatic ROS1-Positive NSCLC and NTRK-positive solid tumors.

Voyager (VYGR) Gains on Gene Therapy Deal With Novartis

by Zacks Equity Research

Voyager (VYGR) enters into a capsid license agreement with Novartis for Huntington's disease and spinal muscular atrophy. The infusion of cash will extend the company's cash runway.

BEAM Stock Rallies More Than 25% in 3 Months: What Next?

by Zacks Equity Research

BEAM is making good progress with its lead pipeline candidate, BEAM-101, which is being developed for treating sickle cell disease. Also, the recent restructuring efforts are expected to reduce costs.

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

by Zacks Equity Research

Roche (RHHBY) is set to acquire LumiraDx's Point of Care technology for $295 million and an additional payment of up to $55 million.

Bayer (BAYRY) Loses 28% in 2023: What to Expect in 2024?

by Zacks Equity Research

Bayer (BAYRY) faced challenges in 2023 as sales declined in the Crop Science division. Pipeline setbacks also weighed on the stock.

Amicus (FOLD) Banks on Galafold, Overdependence a Concern

by Zacks Equity Research

Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.

Iovance (IOVA) Falls After Clinical Update on Lung Cancer Drug

by Zacks Equity Research

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.

Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody

by Zacks Equity Research

The FDA approves Coherus' (CHRS) Udenyca Onbody, an on-body injector presentation of Udenyca (pegfilgrastim-cbqv). Shares of the company rise on the news.

Senti Bio (SNTI) Rises as FDA Clears IND for Cancer Candidate

by Zacks Equity Research

The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.

Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis

by Zacks Equity Research

Cidara's (CDTX) Rezzayo (rezafungin acetate) gets approval from the European Commission for the treatment of invasive candidiasis in adults. The stock rises 11.1%.

Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal

by Zacks Equity Research

Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.

Sanofi (SNY) Discontinues Tusamitamab Ravtansine Cancer Program

by Zacks Equity Research

Sanofi (SNY) stops the development of tusamitamab ravtansine after a phase III study on the candidate for second-line metastatic non-small cell lung cancer fails to meet the primary endpoint.